#BlueNovember
withRadiotheranostics

Emphasizing the value of radiotheranostics in detection and multidisciplinary care.

#BlueNovember
withRadiotheranostics

This November, we bring together Urology, Oncology, and Nuclear Medicine to advance prostate cancer care, highlighting the benefits of integrating radiotheranostics into the prostate cancer care pathway and practical ways to implement it.

First things, first: Early Detection

In collaboration with PRAISE-U

Screening

PRAISE-U is a consortium that works to encourage early detection and diagnosis of prostate cancer through customized and risk-based screening programs. Here you can access downloadable quick references detailing European health system backgrounds, local screening practices, the state of play, and recommendations.

FACT SHEETS

When to use PSMA PET scan in early disease

Discover Ontario Institute for Cancer Research's educational videos for professionals on PSMA PET/CT imaging and its role in prostate cancer care, developed with leading radiation oncology and nuclear medicine experts to improve diagnosis, staging, and treatment planning.

TeaserPSMA PET Prostate Cancer Radiation Therapy - Series Teaser
OverviewPSMA PET Prostate Cancer Radiation Therapy – Overview
Pratical Session 1PSMA PET Prostate Cancer Radiation Therapy – Primary and Salvage RT, Practical Session 1
Pratical Session 2PSMA PET Prostate Cancer Radiation Therapy – Recurrent/Metastatic Disease, Practical Session 2
Glenn Bauman, MD, FRCPC
Dr. Bauman is a Radiation Oncologist specializing in Genitourinary and Central Nervous System Malignancies. He is also the Professor and Chair/Chief of the Department of Oncology at the Schulich School of Medicine and Dentistry, University of Western Ontario in London, Ontario and is a Scientist, London Health Sciences Centre Research Institute. Dr. Bauman’s primary areas of clinical practice are in genitourinary and central nervous system tumors and areas of research interest are multi-modality image guided radiotherapy and cancer imaging.

The VISION Trial: Meet Dr Alison Armour 

The VISION Trial: Meet Dr Alison Armour

Dr Alison Armour, MD., FRCP., FRCR, is an oncologist and global leader in radiopharmaceutical innovation. She was instrumental in the clinical development of the first approved PSMA-targeted radioligand therapy for metastatic prostate cancer. During her time as Chief Medical Officer at Endocyte, she helped design and lead the landmark VISION trial, establishing radiotheranostics as a new standard of care in prostate cancer.

Can you discuss the rationale for choosing Lutetium-177 as the radionuclide for PSMA-617?

Lutetium-177 had the most clinical experience and practical advantages as it has a 6.7-day half-life support in manufacturing and distribution.  Beta emissions have a shorter path length than some isotopes like Yttrium-90 or Iodine-131, reducing bone marrow toxicity.  In patients with high tumor burden, initial cycles concentrate radiation in tumors. As tumors shrink, normal tissues may receive more exposure—an important consideration for later cycles.

READ THE FULL INTERVIEW

Refer a patient

Radioligand Therapy can improve patients' quality of life. If you’re ready to refer a patient but don’t know where to start, our global map makes it easy: discover over 1,000 centers worldwide offering this life-changing treatment.

Radioligand Therapy Centers >>

#BlueNovember
WithRadiotheranostics

During November, each week, we’ll share new content showcasing the benefits of integrating radiotheranostics into the prostate cancer care pathway — and practical ways to implement it. Stay tuned!